A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up

Trial Profile

A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Insulin (Primary) ; Antihyperglycaemics
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors MannKind Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Oct 2014 Planned End Date changed from 1 Dec 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 23 Oct 2014 Planned primary completion date changed from 1 Aug 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top